On February 21, 2025, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order determining that the semaglutide ...
The report suggests compounders may be using illegally imported APIs made in unregistered overseas facilities.
Cash position of €7.5 million as of December 31, 2024 BioChaperone Lispro final dosing of Phase 3 triggered a $10 million revenue recognition, and top-line data are expected in mid-2025 ...